玻璃体内抗VEGF药物治疗糖尿病合并妊娠DR的研究进展  

Research Progress of Intravitreal Anti-VEGF Drugs in the Treatment of Diabetes Complicated with Gestational DR

作　　者：曾倩倩 ZENG Qianqian(Dalian Medical University,Dalian 116044,China)

机构地区：[1]大连医科大学,辽宁大连116044

出　　处：《中外医学研究》2023年第12期172-176,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：糖尿病和糖尿病合并妊娠是全世界关注的领域。妊娠本身是糖尿病进展的危险因素,妊娠期间发生的代谢、血管、免疫和激素等生理变化可导致糖尿病视网膜病变(DR)的发展和恶化。血管内皮生长因子(VEGF)是参与DR的最重要的介质之一,它的异常产生与释放会诱导新生血管的形成。玻璃体内注射抗VEGF药物被广泛用于治疗DR,然而,其对于胎儿和母亲的健康影响证据非常有限。本文对妊娠与DR、VEGF与糖尿病合并妊娠DR的关系及抗VEGF药物治疗糖尿病合并妊娠DR的研究与风险进行综述,旨在为妊娠期间抗VEGF药物治疗提供依据。Diabetes and diabetes complicated with pregnancy are areas of worldwide concern.Pregnancy itself is a risk factor for the progression of diabetes,metabolic,vascular,immune and hormonal etc physiological changes occurring during pregnancy can lead to the development and exacerbation of diabetic retinopathy(DR).Vascular endothelial growth factor(VEGF)is one of the most important mediators involved in DR,and its abnormal production and release can induce the formation of new blood vessels.Intravitreal injection of anti-VEGF drugs is widely used to treat DR.However,the evidence for its impact on the health of fetuses and mothers is very limited.This article reviewed the relationship between pregnancy and DR,VEGF and diabetes complicated with gestational DR,and the research and risk of anti-VEGF drugs in the treatment of diabetes complicated with gestational DR,aiming to provide a basis for anti-VEGF drugs treatment during pregnancy.

关 键 词：糖尿病视网膜病变 妊娠期 血管内皮生长因子 抗血管内皮生长因子药物 

分 类 号：R714.256[医药卫生—妇产科学] R774.1[医药卫生—临床医学]